Business
Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will begin screening its library of novel
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection.\n\n\nADX-629 and reproxalap are structurally related to chloroquine and hydroxychloroquine, drugs currently in clinical testing for the treatment of COVID-19 infection.\n\n\n“We are committing scientific expertise and development resources associated with our RASP platform to help reduce the impact of the COVID-19 global healthcare crisis,” stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “Given the strong association between RASP and acute respiratory distress syndrome (ARDS), as well as the structural similarity of reproxalap and ADX-629 to chloroquines, we are researching the potential of our novel RASP inhibitors to mitigate the clinical severity of COVID-19 infection.”\n\n\nReproxalap1 and ADX-6292 have been shown to diminish inflammation in animal models of cytokine storm. Reproxalap has also demonstrated preliminary activity in a preclinical model of ARDS3.\n\n\nAldeyra also announced that, in response to a recent U.S. Department of Health and Human Services solicitation, Aldeyra has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) for the development of ADX-629 for the treatment of COVID-19 infection. ADX-629 has completed a single and multiple ascending dose Phase 1 clinical trial. Initiation of a Phase 2 clinical trial of ADX-629 in patients with immune-mediated disease is planned for the second half of 2020.\n\n\nAldeyra is also seeking healthcare industry partners that may be interested in testing ADX-629 pursuant to the U.S. Food and Drug Administration’s Emergency Use Authorization guidelines. Physicians wishing to use ADX-629 under a single patient Investigational New Drug (IND) application for Compassionate or Emergency Use should email Dr. James Gow, Senior Vice President of Clinical Development, at [email protected].\n\n\n“We believe that ADX-629 could potentially be an important tool for physicians treating patients who are experiencing ARDS associated with COVID-19, either as a single agent or as an adjunct to other therapie...